RBC Capital Maintains Outperform on BioCryst Pharma, Lowers Price Target to $13

Benzinga Newsdesk www.benzinga.com Negative 95.5%

Neg 95.5% Neu 0% Pos 0%

RBC Capital analyst Brian Abrahams maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and lowers the price target from $14 to $13.